 Viking Therapeutics recently reported their Q1 earnings that revealed the company still has a strong cash position to help fund their impressive pipeline of metabolic and endocrine therapeutic candidates. VK2809 and VK0214 could be best-in-class products that bring in significant revenue. Sadly, VKTX is trading as if the company is DOA. I check for a pulse. 